ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533 IND cleared by FDA; initiation…
Pharmaceuticals, Biotechnology and Life Sciences
ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533 IND cleared by FDA; initiation…
– Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022- – $121.2 million in cash as…
DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission Dosed the First Patients in…
MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced…
U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); On…
– Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021…
BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to…
Potential to provide approximately $15 million a year in savings for life-enhancing medicationsSANTA MONICA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE)…
NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical,…
TORONTO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an…